Oxidation pattern of the anticancer drug ellipticine by hepatic microsomes - Similarity between human and rat systems

General Physiology and Biophysics

Volumn 25, Issue 3, 2006, Pages 245-261

  Stiborová, Marie ^a   Borek Dohalska L ^a   Aimova D ^a   Kotrbova V ^a   Kukackova K ^a   Janouchova K ^a   Rupertova M ^a   Ryslava H ^a   Hudecek J ^a   Frei, E ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Anticancer drug; Cytochrome P450; Ellipticine; Metabolism; Oxidation

Indexed keywords

12 HYDROXYELLIPTICINE; 13 HYDROXYELLIPTICINE; 7 HYDROXYELLIPTICINE; 9 HYDROXYELLIPTICINE; ANTINEOPLASTIC AGENT; CYTOCHROME P450; CYTOCHROME P450 1A; DRUG METABOLITE; ELLIPTICINE; ELLIPTICINE DERIVATIVE; ELLIPTICINE OXIDE; LIVER ENZYME;

ANIMAL TISSUE; ARTICLE; CATALYSIS; CONTROLLED STUDY; DNA ADDUCT; DRUG OXIDATION; DRUG STRUCTURE; HUMAN; HUMAN TISSUE; HUMAN VERSUS ANIMAL COMPARISON; LIVER MICROSOME; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; ORTHOLOGY; PROTEIN EXPRESSION; RABBIT; RAT; SPECIES COMPARISON; SPECIES DIFFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DNA ADDUCTS; ELLIPTICINES; ENZYME INHIBITORS; HUMANS; HYDROXYLATION; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICROSOMES, LIVER; OXIDATION-REDUCTION; RABBITS; RATS; RATS, WISTAR; SPECIES SPECIFICITY;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 33845240192     PISSN: 02315882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Auclair C. (1987): Multimodal action of antitumor agents on DNA: The ellipticine series. Arch. Biochem. Biophys. 259, 1-14
2. Boogaard A. T., Pandit U. K., Koomen G. J. (1994): Ring-D modifications of ellipticine. Part 2. Chlorination of ellipticine via its N-oxide and synthesis and selective acetylation of 5,6,11-trimethyl-5H benzo[B]carbazole. Tetrahedron 50, 4811-4828
3. Bořek-Dohalskí L., Hodek P., Sulc M., Stiborová M. (2001): α-Naphthoflavone acts as activator and reversible or irreversible inhibitor of rabbit microsomal CYP3A6. Chem. Biol. Interact. 138, 85-106
4. Boŕek-Dohalskí L., Frei E., Stiborová M. (2004): DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 cells. Collect. Czech. Chem. Commun. 69, 603-615
5. Chu Y., Hsu M. T. (1992): Ellipticine increases the superhelical density of intracellular SV40 DNA by intercalation. Nucleic Acids Res. 20, 4033-4038
6. DeMarini D. M., Abu-Shakra A., Gupta R., Hendee L. J., Levine J. G. (1992): Molecular analysis of mutations induced by the intercalating agent ellipticine at the hisD3052 allele of Salmonella typhimurium TA98. Environ. Mol. Mutagen. 20, 12-18
7. El-Rayes B. F., Ali S., Heilbrun L. K., Labsbidi S., Bouwman D., Visscher D., Philip P. A. (2003): Cytochrome P450 and glutathione transferase expression in human breast cancer. Clin. Cancer Res. 9, 1705-1709
8. Fossé P., René B., Charra M., PaoIetti C., Saucier J. M. (1992): Stimulation of topoi-somerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationships. Mol. Pharmacol. 42, 590-595
9. Frei E., Bieler C., Arlt V. M., Wiessler M., Stiborovi M. (2002): Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected. with human cytochrome P450 enzymes. Biochem. Pharmacol. 64, 289-295
10. Foelich-Ammon S. J., Patchan M. W., Osheroff N., Thompson R. B. (1995): Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy. J. Biol. Chem. 270, 14998-15004
11. Gut I., Nedelcheva V., Souček P., Stopka P., Vodička P., Gelboin, H. V., Ingelman-Sundberg M. (1996): The role of CYP2E1 and 2131 in metabolic activation of benzene derivatives. Arch. Toxicol. 71, 45-56
12. Haugen D. A., Coon M. J. (1976): Properties of electrophoretically homogeneous phenobarbital-inducible and β-naphthoflavone-inducible forms of liver microsomal cytochrome P-450. J. Biol. Chem. 251, 7929-7939
13. Hofle G., Glase N., Leibold T., Sefkow M. (1999): Epothilone A-D and their thiazole-modified analogs as novel anticancer agents. Pure Appl. Chem. 71, 2019-2024
14. Lesca P., Beaune P., Monsarrat B. (1981a): Ellipticines and human liver microsomes: spectral interaction with cytochrome P-450 and hydroxylation. Inhibition of aryl hydrocarbon metabolism and mutagenicity. Chem. Biol. Interact. 36, 299-309
15. Lesca P., Monsarrat B., Cross S., Paoletti P. (1981b): Influence of inducers of monooxygenases on cytotoxic efficiency of ellipticine on leukemia L1210 cells. J. Natl. Cancer Inst. 67, 871-876
16. Modi S. P., Michael M. A., Archer S., Carey J. J. (1991): An efficient synthesis of C-11 substituted 6H-pyrido[4,3-b]carbazoles. Tetrahedron 47, 6539-6548
17. Monnot M., Mauffret O., Simon V., Lescot E., Psaume B., Saucier J. M., Charra M., Belehradek J. Jr., Fermandjian. S. (1991): DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J. Biol. Chem. 25, 1820-1829
18. Murray G. I., Weaver R. J., Paterson P. J., Ewen S. W., Melvin W. T., Burke M. D. (1993): Expression of xenobiotic metabolizing enzymes in breast cancer. J. Pathol. 169, 347-353
19. Murray G. I., Melvin W. T., Burke M. (1995): Cytochrome P450 expression in tumors. J. Pathol. 3, 147-152
20. Nicolaou K. C., Ritzén A., Namoto K. (2001): Recent developments in the chemistry, biology and medicine of the epothilones. Chem. Commun. 1523-1535
21. Omura T., Sato R. (1964): The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239, 2370-2378
22. Patterson L. H., McKeown S. R., Robson T., Gallagher R., Raleigh S. M., Orr S. (1999): Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anticancer Drug Des. 14, 473-486
23. Poljaková J., Stiborová M. (2004): Peroxidase-mediated ellipticine-DNA adduct formation explains the selective efficiency of this anticancer drug against breast cancer and leukemia. Chem. Listy 98, 298
24. Ratclife A. J., Sainsbury M., Smith A. D. (1988): Chemistry of 6H-pyrido[4,3-b]carbazoles. Part 12. Synthesis of potential bisintercalating drug bearing two ellipticine units. J. Chem. Soc. Perkin Trans. I 1988, 2933-2941
25. Rendic S., DiCarlo F. J. (1997): Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab. Rev. 129, 413-480
26. Singh M. P., Hill G. C., Peoch D., Rayner B., Inabach J. L., Lown J. W. (1994): Highfield NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry 33, 10271-10285
27. Stiborová M., Asfaw B., Anzenbacher P., Legetický L., Hodek P. (1988): The first identification of the benzenediazonium ion formation from a non-aminoazo dye, 1-phenylazo-2-hydroxynaphthalene (Sudan I) by microsomes of rat livers. Cancer Lett. 40, 319-326
28. Stiborová M., Asfaw B., Frei E., Schmeiser H. H., Wiessler M. (1995): Benzenediazonium ion derived from Sudan I forms an 8-(phenylazo)guanine adduct in DNA. Chem. Res. Toxicol. 8, 489-498
29. Stiborová M., Bieler C. A., Wiessler M., Rei E. (2001): The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem. Pharmacol. 62, 1675-1684
30. Stiborová M., Botek-Dohalská L., Hodek P., Mráz J., Frei E. (2002): New selective inhibitors of cytochromes P450 2B and their application to antimutagenesis of tamoxifen. Arch. Biochem. Biophys. 403, 41-49
31. Stiborová M., Breuer A., Aimová D., Stiborová-Rupertová M., Wiessler M., Frei E. (2003a): DNA adduct formation by the anticancer drug ellipticine in rats determined by 32 P-postlabeling. Int. J. Cancer 107, 885-890
32. Stiborová M., Stiborová-Rupertová M., Bořek-Dohalská L., Wiessler M., Frei E. (2003b): Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem. Res. Toxicol. 16, 38-47
33. 2-oxide. Cancer Res. 64, 8374-8380
34. Stiborová M., Poljaková J., Ryšlavá H., Dračnský M., Eckschlager T., Frei E. (2006): Mammalian peroxidases activate ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyellipticine. Int. J. Cancer (in press)
35. Tassaneeyakul W., Birkett D. J., Veronese M. E., McManus M. E., Tukey R. H., Quattrochi L. C., Gelboin H. V., Miners J. O. (1993): Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J. Pharmacol. Exp. Ther. 265, 401-407
36. Ueng Y.-F., Kuwabara T., Chun Y.-J., Guengerich F. P. (1997): Cooperativity in oxidation catalyzed by cytochrome P450 3A4. Biochemistry 36, 370-381
37. Wiechelman K. J., Braun R. D., Fitzpatrick J. D. (1988): Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation. Anal. Biochem. 175, 231-237
38. Wijsmuller W. F. A., Warner M. J., Koonen G. I., Pandit U. K. (1986): Pyridocarbazole alkaloids. Synthesis of olivacine and ellipticine analogues. Heterocycles 24, 1795-1797